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BACKGROUND: No studies measure preference-based utilities in advanced melanoma that capture both intended clinical response and
unintended toxicities associated with treatment.
METHODS: Using standard gamble, utilities were elicited from 140 respondents in the United Kingdom and Australia for 13 health
states.
RESULTS: Preferences decreased with reduced treatment responsiveness and with increasing toxicity.
CONCLUSION: These general population utilities can be incorporated into treatment-specific cost-effectiveness evaluations.
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Advanced metastatic melanoma is almost uniformly fatal, with
median survival ranging from 6 to 8 months (Korn et al, 2008).
Therapy aims at maximising symptom control, minimising
toxicity, and optimising the quality of life (Kiebert et al, 2003).
Health status utility assessments enable the quantification of
preferences for health outcomes and the estimation of quality-
adjusted life expectancy. Utility measurement in melanoma to date
has primarily focused on toxicities associated with interferon
(IFN) therapy (Kilbridge et al, 2001; Dixon et al. 2006). No studies
have obtained utilities for a broader set of health states that
capture both the intended (clinical response) and unintended
(toxicity) effects of available treatments for advanced melanoma.
Clinical response may specifically have a substantial impact on
preferences. For example, high levels of treatment-specific
optimism have been associated with less depression at both the
beginning and end of treatment for metastatic melanoma (Cohen
et al, 2001). The purpose of this study was to measure preferences
for a universal set of standardised health states that include clinical
response and toxicities during treatment of advanced melanoma.
METHODS
A cross-sectional study was conducted in the United Kingdom and
Australia to elicit utilities for advanced melanoma health states
among, as recommended by the UK National Institute for Clinical
Excellence, members of the general public (NICE, 2004). Trained
interviewers used the standard gamble technique, which involves
making decisions under conditions of uncertainty (Torrance, 1986).
Respondents imagine that they are in a selected health state. They
can remain in that state, or take a gamble that involves a chance (p)
of achieving full health with a corresponding chance (1 p)o fb e i n g
dead. The p probabilities are varied using a ping-pong approach,
converging on p¼50%, until the respondent is indifferent between
the two options. For each health state, the respective utility equals the
probability p of full health at the point at which the respondent is
indifferent between remaining in the health state and taking the
gamble. Utility scores range from 0.0, reflecting being dead, to 1.0,
reflecting full health.
Respondents were recruited from the United Kingdom and
Australia in December 2007. All participants provided informed
consent and received compensation for their time. This study was
approved by the Independent Investigational Review Board
(Plantation, FL, USA) and complied with the tenets of the
Declaration of Helsinki.
Health state development
Four melanoma treatment-related response states, one sympto-
matic melanoma state, and nine toxicity-related health states were
developed on the basis of published literature. Specifically,
treatment response status was described on the basis of the World
Health Organisation’s definition for all cancers (WHO, 1979).
Partial response state was based on a 450% decrease in lesion
mass; stable disease was based on a o25% decrease or increase in
lesion mass; and progressive disease (PD) was based on the
appearance of new lesions or increase by 425% in lesion mass. In
addition, a best supportive care (BSC) state represented no
indicated or desired cancer treatment, and a symptomatic
melanoma health state represented symptoms experienced in
advanced melanoma.
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grade I/II toxicities (occurring in X10% of treated patients) from
published and unpublished literature, and product inserts for
ipilimumab, dacarbazine, temozolomide, interleukin-2, fotemus-
tine, and IFN-a. Grade III/IV toxicities were described in two
health states: one involving outpatient treatment for 1–2 days and
the other involving hospitalisation for 2–5 days. Toxicity health
state descriptions were developed using the Common Terminology
Criteria for Adverse Events (Cancer Therapy Evaluation Program,
2006). One melanoma treatment, ipilimumab, may be associated
with immune-related adverse events that may lead to therapeutic
benefit (Downey et al, 2007; O’Day et al, 2007). Thus, for
exploratory purposes, we included a health state for partial
response plus toxicity as indication that treatment is working.
The health states were described as being treated for cancer
(melanoma was not specified), whether or not treatment is
working, and changes in tumour size, pain levels, appetite, effort
required to perform daily activities, and fatigue. Each of the
toxicity descriptions was described in association with partial
response so that the respective utility decrements for toxicities
could be calculated by subtracting the utility for partial response
from the utility of the toxicity state. All health states were labelled
with symbols to avoid imposing a predetermined hierarchical
order on the states. The descriptions were developed in layperson
terms, and health states were refined after an iterative review by
five clinical experts, two oncology nurses, three quality-of-life
researchers, and a pilot test with individuals from the general
public.
RESULTS
There were a total of 140 participants, 77 from Australia and 63
from the United Kingdom, included in the analysis. The mean
respondent age was 45±14 years, and 48% were male. The samples
were well matched according to the demographic distributions of
their target adult populations (England and Wales Census, 2001/
2007; Australian Bureau of Statistics, 2007a,b).
Table 1 reports the mean utilities for the health states. Partial
response was most preferred, followed by stable disease, and PD
and BSC were equivalently valued within countries. A comparison
between countries revealed higher mean utilities in Australia than
in the United Kingdom for partial response (0.91 vs 0.85; Po0.001)
and stable disease (0.83 vs 0.77; P¼0.018). However, mean utilities
were lower among Australians compared with those from the
United Kingdom for the least favoured health states of PD (0.47 vs
0.59; P¼0.001) or BSC (0.46 vs 0.59; Po0.001). Mean utilities did
not differ by age or sex.
The higher mean utility for partial response observed in
Australia relative to the United Kingdom translated into toxicities
being valued less favourably by Australian respondents when
considered as toxicity-specific utility decrements. (These decre-
ments can be added to the utilities for each of the base states (CR,
PR, SD, and PD), as applicable.) Hair loss had the smallest utility
decrement in both countries (–0.03) and hospitalisation for grade
III/IV toxicity had the greatest utility decrement ( 0.13 (United
Kingdom) vs  0.20 (Australia)). Symptomatic melanoma was also
the least preferred, with values similar to hospitalisation for grade
II/IV toxicity. The exploratory health state, toxicity as an
indication that treatment is working, was associated with similar
decrements between the countries of Australia ( 0.08) and the
United Kingdom ( 0.09) (data not shown).
DISCUSSION
This study yielded general population utilities for a universal set of
advanced melanoma health states. These utilities can assist in the
evaluation of melanoma treatments in future studies. As may be
expected, preferences for health states decreased with reduced
treatment responsiveness and with an increasing grade of
treatment-related toxicity.
The development of health state vignettes made it possible to
gauge the impact of knowledge of treatment response on
individual preferences: the mean utility for partial response was
higher than that for stable disease by 0.08 in both Australia and the
United Kingdom. In addition, the utility decrement for the
exploratory health state describing severe toxicity that may be
indicative of the treatment working was approximately twice as
favourable, relative to the other severe grade III/IV toxicity states
( 0.08 vs  0.13 and  0.17). Using a vignette approach allowing
for descriptions of clinical response vs a generic utility ques-
tionnaire such as the EQ-5D can lead to different estimates of
comparative effectiveness. Specifically, decreases in quality-of-life
during IFN-a treatment for advanced melanoma were offset by
reduced risk of recurrence and mortality when vignette-based
utilities were applied (Kilbridge et al, 2002; Crott, 2004; Crott et al,
2004). In contrast, IFN was only marginally better in treating
melanoma than was BSC when generic EQ-5D utilities were used
(Dixon et al, 2006).
More research is needed on the impact of prognosis on
treatment-related utilities. Hope is a powerful influence and a
key factor in finding the motivation to continue being positive
about life (Cohen et al, 2001). Therefore, it is not too surprising
that knowing that treatment is working translates into a high
utility. However, it is unknown how different lengths of perceived
survival impact a patient’s hope and preferences. Richardson et al
(1996) found that utilities for a multi-phase health scenario
covering 16 years were not commensurate with conventionally
calculated quality-adjusted life years, the sum of the years in each
health state multiplied by the utility for each state. They found that
knowledge of future suffering and death casts a shadow over (or
devalues) enjoyment of the earlier years. However, as the
researchers discuss, patients would normally be provided with
information on possible prognosis and not given a scenario
wherein outcome is deterministic. In this regard, the approach
used in our study may be preferable, given that prognosis is a key
influential component in the assignment of health state utilities.
We observed significant differences in mean health state utilities
between countries for the clinical response states. Relative to UK
respondents, Australians reported a lower impact of the less-severe
Table 1 Mean utilities of base states and utility decrements associated
with treatment toxicities
Health state
All
mean (s.e.)
Australia
mean (s.e.)
UK
mean (s.e.)
Clinical response states
Partial response 0.88 (0.01) 0.91 (0.01) 0.85 (0.02)
Stable disease 0.80 (0.01) 0.83 (0.01) 0.77 (0.02)
Progressive disease 0.52 (0.02) 0.47 (0.03) 0.59 (0.02)
Best supportive care 0.52 (0.02) 0.46 (0.03) 0.59 (0.02)
Utility decrement for toxicity states
Hair loss (grade I/II)  0.03 (0.01)  0.03 (0.01)  0.03 (0.01)
Skin reaction (grade I/II)  0.06 (0.01)  0.08 (0.01)  0.03 (0.01)
Diarrhoea (grade I/II)  0.09 (0.01)  0.11 (0.01)  0.06 (0.01)
Nausea/vomiting (grade I/II)  0.10 (0.01)  0.12 (0.01)  0.07 (0.01)
Flu-like syndrome (grade I/II)  0.11 (0.01)  0.13 (0.01)  0.09 (0.01)
Stomatitis (grade I/II)  0.13 (0.01)  0.14 (0.01)  0.10 (0.02)
1-day in-/outpatient stay for
severe toxicity (grade III/IV)
 0.13 (0.01)  0.14 (0.01)  0.11 (0.02)
Symptomatic melanoma
a  0.16 (0.01)  0.20 (0.02)  0.11 (0.02)
2–5-day hospitalisation for
severe toxicity (grade III/IV)
 0.17 (0.01)  0.20 (0.02)  0.13 (0.02)
aNot a treatment-related toxicity; describes symptoms associated with progressive
melanoma.
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response states. Similarly, studies using indirect methods, such as the
EQ-5D, to estimate patient preferences have shown quite large inter-
country differences, including in patients with cancer (Sullivan et al,
2005; Pickard et al, 2007). The higher mean utility for partial
response in Australia relative to that in the United Kingdom
translated into toxicities being valued less favourably by Australian
respondents when considered as toxicity-specific utility decrements.
It is unknown whether the magnitude of utility decrements for
toxicities would be influenced by using stable disease as the base
state instead of partial response. Moreover, coupling toxicities with
a disease state limits the opportunity to measure the true
contribution of each component to the resulting utilities. However,
combining these various impacts more truly reflects reality. For
future applications, these decrements can be coupled with the
utility of any respective clinical response, as applicable. However,
analysts should be cautious when applying the utility estimates
from this study, keeping in mind that the differences observed in
toxicity state utilities were driven by the different utilities assigned
to the base case of partial response.
This study did not include a health state for complete response.
If included, respondents would be required to imagine that they
had melanoma but that it was in complete remission; we felt that
this may be too complex an undertaking to include as a part of the
standard gamble exercise. However, an estimate for living disease
free has been reported by Kilbridge as 0.96 (Kilbridge et al, 2001).
In addition, our study did not consider health states with multiple
toxicities. Several recent studies have explored the estimation of
utilities given this scenario. Dale et al (2002) and Fu and Kattan
(2008) recommend using a minimum model, which predicts a
joint-state utility as being equal to the lower of the two given
single-state utilities for an individual. However, Flanagan et al.
(2006) recommend the use of a multiplicative model. Further
research is needed in this area.
The study reports general population health state utilities from
the United Kingdom and Australia for a universal set of advanced
melanoma health states, including potential clinical responses and
toxicities associated with various treatments. This study used a
rigorous process for the development of standardised health states
that incorporated both intended treatment responses and unin-
tended events. The utilities generated in this study can be applied
in future cost-effectiveness analyses of treatment for advanced
melanoma, as well as those for the treatment of potentially other
types of advanced cancer with similar prognoses.
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